These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18371466)

  • 1. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design.
    Pfisterer M; Bertel O; Bonetti PO; Brunner-La Rocca HP; Eberli FR; Erne P; Galatius S; Hornig B; Kiowski W; Pachinger O; Pedrazzini G; Rickli H; De Servi S; Kaiser C;
    Am Heart J; 2008 Apr; 155(4):609-14. PubMed ID: 18371466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
    Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
    J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET.
    Pfisterer M; Brunner-La Rocca HP; Rickenbacher P; Hunziker P; Mueller C; Nietlispach F; Leibundgut G; Bader F; Kaiser C;
    Eur Heart J; 2009 Jan; 30(1):16-24. PubMed ID: 19033260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions.
    Jeger RV; Schneiter S; Kaiser C; Bonetti PO; Brunner-La Rocca H; Handke M; Osswald S; Buser PT; Pfisterer ME;
    Cardiology; 2009; 112(1):49-55. PubMed ID: 18580059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study).
    Rahel BM; Laarman GJ; Kelder JC; Ten Berg JM; Suttorp MJ
    Am Heart J; 2009 Jan; 157(1):149-55. PubMed ID: 19081412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Gwon HC; Hahn JY; Park KW; Song YB; Chae IH; Lim DS; Han KR; Choi JH; Choi SH; Kang HJ; Koo BK; Ahn T; Yoon JH; Jeong MH; Hong TJ; Chung WY; Choi YJ; Hur SH; Kwon HM; Jeon DW; Kim BO; Park SH; Lee NH; Jeon HK; Jang Y; Kim HS
    Circulation; 2012 Jan; 125(3):505-13. PubMed ID: 22179532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
    Garg P; Normand SL; Silbaugh TS; Wolf RE; Zelevinsky K; Lovett A; Varma MR; Zhou Z; Mauri L
    Circulation; 2008 Nov; 118(22):2277-85, 7p following 2285. PubMed ID: 19001019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stents versus coronary-artery bypass grafting for left main coronary artery disease.
    Seung KB; Park DW; Kim YH; Lee SW; Lee CW; Hong MK; Park SW; Yun SC; Gwon HC; Jeong MH; Jang Y; Kim HS; Kim PJ; Seong IW; Park HS; Ahn T; Chae IH; Tahk SJ; Chung WS; Park SJ
    N Engl J Med; 2008 Apr; 358(17):1781-92. PubMed ID: 18378517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design.
    Jeger R; Pfisterer M; Alber H; Eberli F; Galatius S; Naber C; Pedrazzini G; Rickli H; Jensen JS; Vuilliomenet A; Gilgen N; Kaiser C
    Am Heart J; 2012 Feb; 163(2):136-41.e1. PubMed ID: 22305828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.
    Camenzind E; Wijns W; Mauri L; Boersma E; Parikh K; Kurowski V; Gao R; Bode C; Greenwood JP; Gershlick A; O'Neill W; Serruys PW; Jorissen B; Steg PG;
    Am Heart J; 2009 Dec; 158(6):902-909.e5. PubMed ID: 19958855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial.
    Kelbaek H; Kløvgaard L; Helqvist S; Lassen JF; Krusell LR; Engstrøm T; Bøtker HE; Jørgensen E; Saunamäki K; Aljabbari S; Thayssen P; Galløe A; Jensen GV; Thuesen L
    J Am Coll Cardiol; 2008 May; 51(21):2011-6. PubMed ID: 18498953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting versus bare metal stenting in acute myocardial infarction. A clinical review.
    Jones WS; Washam JB; Meine TJ; Patel MR
    Minerva Cardioangiol; 2009 Oct; 57(5):585-95. PubMed ID: 19838149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials.
    Kumbhani DJ; Bavry AA; Kamdar AR; Helton TJ; Bhatt DL
    Am Heart J; 2008 Apr; 155(4):640-7. PubMed ID: 18371470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
    Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
    Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients.
    Miglionico M; Patti G; D'Ambrosio A; Di Sciascio G
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):600-4. PubMed ID: 18360849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.